Apatinib for Advanced Non-squamous Head and Neck Cancer

Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study ID
NCT02989259
Phase
PHASE2
Status
Unknown

Conditions

  • Head and Neck Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

In this study, the investigators try to evaluate the efficacy and safety of apatinib in advanced non-squamous head and neck cancer and to validate the correlative biomarkers.

Key Dates

Start date
Dec 31, 2016
Status verified
Dec 2016
Primary completion
Dec 31, 2018
Completion
Dec 31, 2021

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: apatinib
    apatinib 500mg p.o. qd

Primary Outcome Measure

Response Rate [ Time Frame: up to 3 years ]

Central Contacts

Related Studies